Parkside Financial Bank & Trust Has $215,000 Stake in Biogen Inc. (NASDAQ:BIIB)

Parkside Financial Bank & Trust decreased its stake in Biogen Inc. (NASDAQ:BIIB) by 6.9% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,408 shares of the biotechnology company’s stock after selling 104 shares during the quarter. Parkside Financial Bank & Trust’s holdings in Biogen were worth $215,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of the stock. Proficio Capital Partners LLC acquired a new stake in Biogen in the 4th quarter valued at $5,028,000. Advisor OS LLC acquired a new position in Biogen in the fourth quarter worth $431,000. Illinois Municipal Retirement Fund boosted its stake in Biogen by 24.3% in the fourth quarter. Illinois Municipal Retirement Fund now owns 62,181 shares of the biotechnology company’s stock worth $9,509,000 after purchasing an additional 12,166 shares in the last quarter. Prasad Wealth Partners LLC acquired a new position in Biogen in the fourth quarter worth $222,000. Finally, BankPlus Trust Department acquired a new position in Biogen in the fourth quarter worth $106,000. Institutional investors and hedge funds own 87.93% of the company’s stock.

Biogen Stock Up 0.4 %

Shares of Biogen stock opened at $140.50 on Friday. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.35 and a quick ratio of 0.90. The company has a market capitalization of $20.57 billion, a P/E ratio of 12.56, a price-to-earnings-growth ratio of 1.51 and a beta of -0.08. The business has a 50-day moving average of $144.43 and a two-hundred day moving average of $168.48. Biogen Inc. has a 1 year low of $128.51 and a 1 year high of $238.00.

Biogen (NASDAQ:BIIB) last posted its quarterly earnings data on Wednesday, February 12th. The biotechnology company reported $3.44 earnings per share for the quarter, topping the consensus estimate of $3.43 by $0.01. Biogen had a return on equity of 14.98% and a net margin of 16.87%. As a group, equities analysts predict that Biogen Inc. will post 15.83 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts have commented on BIIB shares. StockNews.com lowered Biogen from a “strong-buy” rating to a “buy” rating in a research note on Saturday, December 28th. Bank Of America (Bofa) reduced their price objective on Biogen from $178.00 to $163.00 and set a “neutral” rating on the stock in a research note on Tuesday, February 11th. BMO Capital Markets reduced their price objective on Biogen from $156.00 to $139.00 and set a “market perform” rating on the stock in a research note on Thursday, February 13th. JPMorgan Chase & Co. cut their price target on Biogen from $220.00 to $210.00 and set a “neutral” rating on the stock in a research note on Monday, November 4th. Finally, Morgan Stanley cut their price target on Biogen from $192.00 to $157.00 and set an “equal weight” rating on the stock in a research note on Thursday, February 13th. Seventeen equities research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $213.33.

Biogen Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.